546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration

BACKGROUND: MK-8591 is a novel, highly potent, nucleoside reverse transcriptase translocation inhibitor (NRTTI) that is in development for the treatment of HIV-1 infection. MK-8591 is not expected to be a perpetrator or victim of drug–drug interactions (DDI), as it does not interact with renal or he...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthews, Randolph, Rudd, Deanne, Fillgrove, Kerry, Fox-Bosetti, Sabrina, Levine, Vanessa, Zhang, Sandra, Tomek, Charles, Stoch, Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255630/
http://dx.doi.org/10.1093/ofid/ofy210.554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255630/
http://dx.doi.org/10.1093/ofid/ofy210.554

Ejemplares similares